查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128606

獸醫腫瘤學市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測

Veterinary Oncology Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 214 Pages | 商品交期: 2-3個工作天內

價格

獸醫腫瘤學市場成長要素

全球獸醫腫瘤學市場預計在2025年達到29億美元，並從2026年的31.5億美元成長至2034年的71.1億美元，預測期內複合年成長率（CAGR）為10.70%。北美將引領全球市場，到2025年佔47.58%的市場佔有率，這主要得益於該地區較高的寵物擁有率、先進的獸醫醫療基礎設施以及對專業癌症診斷和治療服務的日益普及。

獸醫腫瘤學專注於伴侶動物（尤其是犬貓）癌症的診斷、治療和管理。該市場涵蓋先進的診斷技術、檢測服務、影像系統、化療藥物、標靶治療、癌症疫苗和支持性護理。寵物日益「人性化」、動物醫療保健支出不斷成長以及人們對癌症早期檢測意識的提高，都顯著推動了市場擴張。分子診斷、液態生物檢體、人工智慧成像和個人化治療方案的持續進步，進一步增強了該行業的成長前景。

獸醫腫瘤學市場趨勢

獸醫腫瘤學市場發展的關鍵趨勢之一是癌症診斷和個人化治療方案的快速進展。獸醫醫院和專科診所擴大採用細胞學、組織病理學、免疫表現型分析、分子診斷、液態生物檢體和人工智慧成像解決方案，以實現更早期、更精準的癌症檢測。這些技術使獸醫能夠更早診斷腫瘤並提案標靶治療方案。同時，標靶癌症療法、淋巴瘤特異性療法、癌症疫苗和輔助治療藥物的出現，正在提高伴侶動物的存活率和生活品質。

市場促進因素

人們對寵物健康和預防性獸醫護理意識的不斷提高是推動獸醫腫瘤學市場成長的主要因素之一。隨著伴侶動物日益被視為家庭成員，寵物飼主也更願意投資先進的診斷測試和癌症治療。老年寵物罹患癌症風險的增加也顯著提升了對腫瘤診斷和治療的需求。此外，新產品的推出、專業動物醫院的擴張以及腫瘤服務可近性的提高也促進了全球市場的發展。

市場限制因素

儘管該市場具有巨大的成長潛力，但仍存在一些阻礙因素。包括化療、放射線治療、標靶治療和特殊診斷在內的先進癌症治療對許多寵物飼主來說仍然很昂貴。開發中國家獸醫腫瘤學專家和先進治療設施的匱乏進一步限制了市場擴張。此外，許多地區寵物保險普及率低，使得治療費用成為沉重的負擔，迫使許多寵物主人選擇基礎治療或安寧療護，而非全面的癌症管理。

市場機遇

獸醫診斷領域的科技創新正在為市場創造巨大的成長機會。諸如血液癌症篩檢、液態生物檢體、數位病理學、人工智慧影像和分子檢測等新型診斷工具，能夠實現癌症的早期發現和更有效的治療方案。這些技術在增加接受腫瘤治療的動物數量的同時，也持續推動對檢測、耗材和監測服務的需求。新興經濟體伴侶動物醫療保健服務的擴張預計也將創造巨大的長期市場機會。

市場區隔

根據產品和服務，市場可分為診斷和治療兩大類。 2025年，由於早期癌症檢測、後續觀察和治療方案製定的重要性日益凸顯，診斷領域將佔市場主導地位。隨著化療、標靶治療和免疫療法的日益普及，治療領域預計將成長更快。

按癌症類型分類，淋巴瘤佔最大的市場佔有率，這主要歸功於其在伴侶動物（尤其是犬類）中較高的診斷率。淋巴瘤特異性藥物的廣泛應用和先進的診斷技術持續推動著這一細分市場的發展。預計在預測期內，肥大細胞瘤也將呈現強勁成長。

就動物種類而言，犬類癌症在全球市場佔主導地位，這主要歸功於犬類癌症高發病率、犬類專用腫瘤治療藥物的廣泛應用以及飼主尋求先進治療方案的強烈意願。隨著大眾意識的提高和治療選擇的增多，貓科動物癌症市場也預計將穩定成長。

區域展望

預計到2025年，北美市場規模將達到13.8億美元，並繼續維持其領先區域市場的地位。該地區受益於完善的獸醫基礎設施、高額的寵物醫療費用支出、廣泛的腫瘤專家群體以及持續的技術創新。美國積極採用先進的伴侶動物醫療保健服務和腫瘤診斷技術，持續推動區域銷售成長。

歐洲是第二大區域市場，這得益於其較高的寵物飼養率、完善的獸醫保健體係以及不斷增加的專科癌症診所。德國和英國等國家持續投資先進的獸醫診斷檢查室和癌症治療服務。

亞太地區預計將成為市場成長最快的地區，這主要得益於中國、日本、印度、韓國和澳洲寵物擁有量的增加，以及都市化、可支配收入的成長和人們對伴侶動物健康保健意識的提高。獸醫醫院和診斷檢查室的擴張也進一步推動了該地區的需求。

在拉丁美洲、中東和非洲，獸醫基礎設施的改善、高品質寵物護理服務的提供以及人們對動物健康意識的提高，正在推動先進癌症診斷和治療的採用，從而導致市場逐步擴張。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第4章：主要考慮因素

  • 2025年主要國家/地區主要疾病盛行率
  • 管道分析：按主要公司分類
  • 概述：獸醫診斷的進展
  • 產業重大發展動態（合併、收購、合作等）
  • 新產品發布：按主要公司分類

第5章：2021-2034年全球獸醫腫瘤學市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品/服務分類。
    • 診斷
      • 依產品
      • 透過方法
    • 治療
      • 藥物類別
      • 按治療類型
  • 市場分析、洞察與預測：按癌症類型分類
    • 淋巴瘤
    • 肥大細胞瘤
    • 黑色素瘤
    • 骨癌
    • 乳腺腫瘤
    • 軟組織肉瘤
    • 血管肉瘤
    • 鱗狀細胞癌
    • 其他
  • 市場分析、洞察與預測：按動物類型分類
    • 狗
    • 貓
    • 馬
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美獸醫腫瘤學市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲獸醫腫瘤學市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區獸醫腫瘤學市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲獸醫腫瘤學市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲獸醫腫瘤學市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • IDEXX Laboratories, Inc.
    • Zoetis Services LLC.
    • Antech Diagnostics, Inc
    • Volition
    • Elanco
    • Dechra Limited
    • Boehringer Ingelheim International GmbH
    • Oncotect
    • Virbac
    • Novavive Inc.
Product Code: FBI117236

Growth Factors of veterinary oncology Market

The global veterinary oncology market was valued at USD 2.90 billion in 2025 and is projected to grow from USD 3.15 billion in 2026 to USD 7.11 billion by 2034, exhibiting a CAGR of 10.70% during the forecast period. North America dominated the global market with a 47.58% market share in 2025, driven by high pet ownership, advanced veterinary healthcare infrastructure, and increasing adoption of specialized cancer diagnosis and treatment services.

Veterinary oncology focuses on the diagnosis, treatment, and management of cancer in companion animals, particularly dogs and cats. The market includes advanced diagnostic technologies, laboratory services, imaging systems, chemotherapy drugs, targeted therapies, cancer vaccines, and supportive oncology treatments. Rising pet humanization, increasing spending on animal healthcare, and growing awareness of early cancer detection are significantly contributing to market expansion. Continuous advancements in molecular diagnostics, liquid biopsy, AI-assisted imaging, and personalized treatment approaches are further strengthening the industry's growth prospects.

Veterinary Oncology Market Trends

A major trend shaping the veterinary oncology market is the rapid advancement of cancer diagnostics and personalized treatment options. Veterinary clinics and specialty hospitals are increasingly adopting cytology, histopathology, immunophenotyping, molecular diagnostics, liquid biopsy, and AI-powered imaging solutions for earlier and more accurate cancer detection. These technologies enable veterinarians to diagnose tumors at earlier stages and recommend targeted treatment plans. At the same time, the availability of targeted cancer drugs, lymphoma-specific therapies, cancer vaccines, and supportive care medications is improving survival rates and enhancing the quality of life for companion animals.

Market Drivers

The increasing awareness of pet health and preventive veterinary care is one of the primary drivers of the veterinary oncology market growth. Pet owners are becoming more willing to invest in advanced diagnostic tests and cancer treatments as companion animals are increasingly regarded as family members. The growing population of aging pets, which are more susceptible to cancer, has significantly increased the demand for oncology diagnostics and therapeutics. In addition, new product launches, expanding veterinary specialty hospitals, and improved access to oncology services are supporting market development worldwide.

Market Restraints

Despite strong growth potential, the market faces several restraints. Advanced cancer treatments, including chemotherapy, radiation therapy, targeted drugs, and specialized diagnostics, remain expensive for many pet owners. Limited availability of veterinary oncology specialists and advanced treatment facilities in developing countries further restricts market expansion. In addition, low penetration of pet insurance in many regions reduces affordability, causing many owners to opt for basic treatment or palliative care instead of comprehensive cancer management.

Market Opportunities

Technological innovation in veterinary diagnostics offers significant growth opportunities for the market. New diagnostic tools such as blood-based cancer screening, liquid biopsy, digital pathology, AI-assisted imaging, and molecular testing enable earlier cancer detection and more effective treatment planning. These technologies increase the number of animals entering oncology care while creating recurring demand for laboratory testing, consumables, and monitoring services. Expanding companion animal healthcare in emerging economies is also expected to generate substantial long-term market opportunities.

Market Segmentation

Based on offering, the market is divided into diagnostics and therapeutics. The diagnostics segment dominated the market in 2025 due to the growing importance of early cancer detection, staging, monitoring, and treatment planning. The therapeutics segment is expected to witness faster growth with increasing adoption of chemotherapy, targeted therapies, and immunotherapy.

By cancer type, lymphoma accounted for the largest market share owing to its high diagnosis rate among companion animals, especially dogs. Availability of lymphoma-specific drugs and advanced diagnostic technologies continues to support this segment. Mast cell tumors are also expected to register strong growth during the forecast period.

Based on animal type, the canine segment dominated the global market due to higher cancer incidence, wider availability of dog-specific oncology treatments, and greater owner willingness to pursue advanced therapies. The feline segment is also expected to grow steadily as awareness and treatment options continue to improve.

Regional Outlook

North America remained the leading regional market with a value of USD 1.38 billion in 2025. The region benefits from strong veterinary infrastructure, high pet healthcare expenditure, widespread availability of oncology specialists, and continuous technological innovation. The U.S. continues to dominate regional revenues through advanced companion animal healthcare services and strong adoption of oncology diagnostics.

Europe represents the second-largest regional market, supported by high companion animal ownership, established veterinary healthcare systems, and increasing availability of specialty oncology clinics. Countries including Germany and the U.K. continue to invest in advanced veterinary diagnostic laboratories and cancer treatment services.

Asia Pacific is expected to witness the fastest market growth due to rising pet ownership, urbanization, increasing disposable income, and growing awareness regarding companion animal healthcare across China, Japan, India, South Korea, and Australia. Expansion of veterinary hospitals and diagnostic laboratories is further strengthening regional demand.

Latin America and the Middle East & Africa are gradually expanding as improving veterinary infrastructure, premium pet care services, and increasing awareness of animal health encourage adoption of advanced cancer diagnostics and treatments.

Competitive Landscape

The veterinary oncology market is moderately fragmented, with leading companies focusing on expanding diagnostic capabilities, oncology drug portfolios, laboratory services, and precision medicine technologies. Major industry participants include IDEXX Laboratories, Inc., Zoetis Services LLC., Antech Diagnostics, Inc., Volition, Elanco, Dechra Limited, Boehringer Ingelheim International GmbH, Oncotect, Virbac, and Novavive Inc. These companies continue investing in cancer screening technologies, AI-assisted diagnostics, targeted therapeutics, and companion animal oncology research to strengthen their competitive position.

Recent developments highlight the industry's rapid innovation. In 2026, Avammune advanced clinical trials for its Enzistat cancer drug in dogs with terminal tumors. During 2025, Yale's canine cancer vaccine program continued multi-center clinical trials, while Cornell University researchers introduced AI-based pathology tools and non-invasive tumor monitoring technologies. These innovations are expected to significantly improve cancer diagnosis and treatment outcomes for companion animals.

Conclusion

The global veterinary oncology market is witnessing strong growth due to increasing pet ownership, rising awareness of animal cancer care, expanding diagnostic capabilities, and continuous innovation in veterinary therapeutics. Valued at USD 2.90 billion in 2025, the market is projected to reach USD 3.15 billion in 2026 and USD 7.11 billion by 2034, supported by advancements in precision diagnostics, personalized treatment approaches, AI-enabled technologies, and growing investment in companion animal healthcare worldwide.

Segmentation By Offering, Cancer Type, Animal Type, and Region

By Offering * Diagnostics

    • By Product
  • Instruments
  • Reagents & Consumables
    • By Technique
  • Cytology
  • Histopathology / Anatomic Pathology
  • Hematology
  • Clinical Biochemistry
  • Immunodiagnostics
  • Molecular Diagnostics
  • Others
  • Therapeutics
    • By Drug Class
  • Cytotoxic Chemotherapy Drugs
  • Targeted Anticancer Drugs
  • Cancer Vaccines
  • Hormonal Drugs
  • Corticosteroids
  • Others
    • By Therapy Type
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Others

By Cancer Type * Lymphoma

  • Mast Cell Tumor
  • Melanoma
  • Osteosarcoma
  • Mammary Tumors
  • Soft Tissue Sarcoma
  • Hemangiosarcoma
  • Squamous Cell Carcinoma
  • Others

By Animal Type * Canine

  • Feline
  • Equine
  • Others

By Region * North America (By Offering, Cancer Type, Animal Type, and Country)

    • U.S.
    • Canada
  • Europe (By Offering, Cancer Type, Animal Type, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Offering, Cancer Type, Animal Type, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Offering, Cancer Type, Animal Type, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Offering, Cancer Type, Animal Type, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries/Region, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Overview: Advancements in Veterinary Diagnostics
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
  • 4.5. New Product Launches, By Key Players

5. Global Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Offering
    • 5.1.1. Diagnostics
      • 5.1.1.1. By Product
        • 5.1.1.1.1. Instruments
        • 5.1.1.1.2. Reagents & Consumables
      • 5.1.1.2. By Technique
        • 5.1.1.2.1. Cytology
        • 5.1.1.2.2. Histopathology / Anatomic Pathology
        • 5.1.1.2.3. Hematology
        • 5.1.1.2.4. Clinical Biochemistry
        • 5.1.1.2.5. Immunodiagnostics
        • 5.1.1.2.6. Molecular Diagnostics
        • 5.1.1.2.7. Others
    • 5.1.2. Therapeutics
      • 5.1.2.1. By Drug Class
        • 5.1.2.1.1. Cytotoxic Chemotherapy Drugs
        • 5.1.2.1.2. Targeted Anticancer Drugs
        • 5.1.2.1.3. Cancer Vaccines
        • 5.1.2.1.4. Hormonal Drugs
        • 5.1.2.1.5. Corticosteroids
        • 5.1.2.1.6. Others
      • 5.1.2.2. By Therapy Type
        • 5.1.2.2.1. Targeted Therapy
        • 5.1.2.2.2. Chemotherapy
        • 5.1.2.2.3. Immunotherapy
        • 5.1.2.2.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.2.1. Lymphoma
    • 5.2.2. Mast Cell Tumor
    • 5.2.3. Melanoma
    • 5.2.4. Osteosarcoma
    • 5.2.5. Mammary Tumors
    • 5.2.6. Soft Tissue Sarcoma
    • 5.2.7. Hemangiosarcoma
    • 5.2.8. Squamous Cell Carcinoma
    • 5.2.9. Others
  • 5.3. Market Analysis, Insights and Forecast - By Animal Type
    • 5.3.1. Canine
    • 5.3.2. Feline
    • 5.3.3. Equine
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Offering
    • 6.1.1. Diagnostics
      • 6.1.1.1. By Product
        • 6.1.1.1.1. Instruments
        • 6.1.1.1.2. Reagents & Consumables
      • 6.1.1.2. By Technique
        • 6.1.1.2.1. Cytology
        • 6.1.1.2.2. Histopathology / Anatomic Pathology
        • 6.1.1.2.3. Hematology
        • 6.1.1.2.4. Clinical Biochemistry
        • 6.1.1.2.5. Immunodiagnostics
        • 6.1.1.2.6. Molecular Diagnostics
        • 6.1.1.2.7. Others
    • 6.1.2. Therapeutics
      • 6.1.2.1. By Drug Class
        • 6.1.2.1.1. Cytotoxic Chemotherapy Drugs
        • 6.1.2.1.2. Targeted Anticancer Drugs
        • 6.1.2.1.3. Cancer Vaccines
        • 6.1.2.1.4. Hormonal Drugs
        • 6.1.2.1.5. Corticosteroids
        • 6.1.2.1.6. Others
      • 6.1.2.2. By Therapy Type
        • 6.1.2.2.1. Targeted Therapy
        • 6.1.2.2.2. Chemotherapy
        • 6.1.2.2.3. Immunotherapy
        • 6.1.2.2.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 6.2.1. Lymphoma
    • 6.2.2. Mast Cell Tumor
    • 6.2.3. Melanoma
    • 6.2.4. Osteosarcoma
    • 6.2.5. Mammary Tumors
    • 6.2.6. Soft Tissue Sarcoma
    • 6.2.7. Hemangiosarcoma
    • 6.2.8. Squamous Cell Carcinoma
    • 6.2.9. Others
  • 6.3. Market Analysis, Insights and Forecast - By Animal Type
    • 6.3.1. Canine
    • 6.3.2. Feline
    • 6.3.3. Equine
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Offering
    • 7.1.1. Diagnostics
      • 7.1.1.1. By Product
        • 7.1.1.1.1. Instruments
        • 7.1.1.1.2. Reagents & Consumables
      • 7.1.1.2. By Technique
        • 7.1.1.2.1. Cytology
        • 7.1.1.2.2. Histopathology / Anatomic Pathology
        • 7.1.1.2.3. Hematology
        • 7.1.1.2.4. Clinical Biochemistry
        • 7.1.1.2.5. Immunodiagnostics
        • 7.1.1.2.6. Molecular Diagnostics
        • 7.1.1.2.7. Others
    • 7.1.2. Therapeutics
      • 7.1.2.1. By Drug Class
        • 7.1.2.1.1. Cytotoxic Chemotherapy Drugs
        • 7.1.2.1.2. Targeted Anticancer Drugs
        • 7.1.2.1.3. Cancer Vaccines
        • 7.1.2.1.4. Hormonal Drugs
        • 7.1.2.1.5. Corticosteroids
        • 7.1.2.1.6. Others
      • 7.1.2.2. By Therapy Type
        • 7.1.2.2.1. Targeted Therapy
        • 7.1.2.2.2. Chemotherapy
        • 7.1.2.2.3. Immunotherapy
        • 7.1.2.2.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 7.2.1. Lymphoma
    • 7.2.2. Mast Cell Tumor
    • 7.2.3. Melanoma
    • 7.2.4. Osteosarcoma
    • 7.2.5. Mammary Tumors
    • 7.2.6. Soft Tissue Sarcoma
    • 7.2.7. Hemangiosarcoma
    • 7.2.8. Squamous Cell Carcinoma
    • 7.2.9. Others
  • 7.3. Market Analysis, Insights and Forecast - By Animal Type
    • 7.3.1. Canine
    • 7.3.2. Feline
    • 7.3.3. Equine
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Offering
    • 8.1.1. Diagnostics
      • 8.1.1.1. By Product
        • 8.1.1.1.1. Instruments
        • 8.1.1.1.2. Reagents & Consumables
      • 8.1.1.2. By Technique
        • 8.1.1.2.1. Cytology
        • 8.1.1.2.2. Histopathology / Anatomic Pathology
        • 8.1.1.2.3. Hematology
        • 8.1.1.2.4. Clinical Biochemistry
        • 8.1.1.2.5. Immunodiagnostics
        • 8.1.1.2.6. Molecular Diagnostics
        • 8.1.1.2.7. Others
    • 8.1.2. Therapeutics
      • 8.1.2.1. By Drug Class
        • 8.1.2.1.1. Cytotoxic Chemotherapy Drugs
        • 8.1.2.1.2. Targeted Anticancer Drugs
        • 8.1.2.1.3. Cancer Vaccines
        • 8.1.2.1.4. Hormonal Drugs
        • 8.1.2.1.5. Corticosteroids
        • 8.1.2.1.6. Others
      • 8.1.2.2. By Therapy Type
        • 8.1.2.2.1. Targeted Therapy
        • 8.1.2.2.2. Chemotherapy
        • 8.1.2.2.3. Immunotherapy
        • 8.1.2.2.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.2.1. Lymphoma
    • 8.2.2. Mast Cell Tumor
    • 8.2.3. Melanoma
    • 8.2.4. Osteosarcoma
    • 8.2.5. Mammary Tumors
    • 8.2.6. Soft Tissue Sarcoma
    • 8.2.7. Hemangiosarcoma
    • 8.2.8. Squamous Cell Carcinoma
    • 8.2.9. Others
  • 8.3. Market Analysis, Insights and Forecast - By Animal Type
    • 8.3.1. Canine
    • 8.3.2. Feline
    • 8.3.3. Equine
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Offering
    • 9.1.1. Diagnostics
      • 9.1.1.1. By Product
        • 9.1.1.1.1. Instruments
        • 9.1.1.1.2. Reagents & Consumables
      • 9.1.1.2. By Technique
        • 9.1.1.2.1. Cytology
        • 9.1.1.2.2. Histopathology / Anatomic Pathology
        • 9.1.1.2.3. Hematology
        • 9.1.1.2.4. Clinical Biochemistry
        • 9.1.1.2.5. Immunodiagnostics
        • 9.1.1.2.6. Molecular Diagnostics
        • 9.1.1.2.7. Others
    • 9.1.2. Therapeutics
      • 9.1.2.1. By Drug Class
        • 9.1.2.1.1. Cytotoxic Chemotherapy Drugs
        • 9.1.2.1.2. Targeted Anticancer Drugs
        • 9.1.2.1.3. Cancer Vaccines
        • 9.1.2.1.4. Hormonal Drugs
        • 9.1.2.1.5. Corticosteroids
        • 9.1.2.1.6. Others
      • 9.1.2.2. By Therapy Type
        • 9.1.2.2.1. Targeted Therapy
        • 9.1.2.2.2. Chemotherapy
        • 9.1.2.2.3. Immunotherapy
        • 9.1.2.2.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 9.2.1. Lymphoma
    • 9.2.2. Mast Cell Tumor
    • 9.2.3. Melanoma
    • 9.2.4. Osteosarcoma
    • 9.2.5. Mammary Tumors
    • 9.2.6. Soft Tissue Sarcoma
    • 9.2.7. Hemangiosarcoma
    • 9.2.8. Squamous Cell Carcinoma
    • 9.2.9. Others
  • 9.3. Market Analysis, Insights and Forecast - By Animal Type
    • 9.3.1. Canine
    • 9.3.2. Feline
    • 9.3.3. Equine
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Offering
    • 10.1.1. Diagnostics
      • 10.1.1.1. By Product
        • 10.1.1.1.1. Instruments
        • 10.1.1.1.2. Reagents & Consumables
      • 10.1.1.2. By Technique
        • 10.1.1.2.1. Cytology
        • 10.1.1.2.2. Histopathology / Anatomic Pathology
        • 10.1.1.2.3. Hematology
        • 10.1.1.2.4. Clinical Biochemistry
        • 10.1.1.2.5. Immunodiagnostics
        • 10.1.1.2.6. Molecular Diagnostics
        • 10.1.1.2.7. Others
    • 10.1.2. Therapeutics
      • 10.1.2.1. By Drug Class
        • 10.1.2.1.1. Cytotoxic Chemotherapy Drugs
        • 10.1.2.1.2. Targeted Anticancer Drugs
        • 10.1.2.1.3. Cancer Vaccines
        • 10.1.2.1.4. Hormonal Drugs
        • 10.1.2.1.5. Corticosteroids
        • 10.1.2.1.6. Others
      • 10.1.2.2. By Therapy Type
        • 10.1.2.2.1. Targeted Therapy
        • 10.1.2.2.2. Chemotherapy
        • 10.1.2.2.3. Immunotherapy
        • 10.1.2.2.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 10.2.1. Lymphoma
    • 10.2.2. Mast Cell Tumor
    • 10.2.3. Melanoma
    • 10.2.4. Osteosarcoma
    • 10.2.5. Mammary Tumors
    • 10.2.6. Soft Tissue Sarcoma
    • 10.2.7. Hemangiosarcoma
    • 10.2.8. Squamous Cell Carcinoma
    • 10.2.9. Others
  • 10.3. Market Analysis, Insights and Forecast - By Animal Type
    • 10.3.1. Canine
    • 10.3.2. Feline
    • 10.3.3. Equine
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. IDEXX Laboratories, Inc.
    • 11.2.2. Zoetis Services LLC.
    • 11.2.3. Antech Diagnostics, Inc
    • 11.2.4. Volition
    • 11.2.5. Elanco
    • 11.2.6. Dechra Limited
    • 11.2.7. Boehringer Ingelheim International GmbH
    • 11.2.8. Oncotect
    • 11.2.9. Virbac
    • 11.2.10. Novavive Inc.

List of Tables

  • Table 1: Global Veterinary Oncology Market Revenue (USD Billion) Forecast, By Offering, 2021-2034
  • Table 2: Global Veterinary Oncology Market Revenue (USD Billion) Forecast, By Diagnostics, 2021-2034
  • Table 3: Global Veterinary Oncology Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 4: Global Veterinary Oncology Market Revenue (USD Billion) Forecast, By Technique, 2021-2034
  • Table 5: Global Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapeutics, 2021-2034
  • Table 6: Global Veterinary Oncology Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 7: Global Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 8: Global Veterinary Oncology Market Revenue (USD Billion) Forecast, By Cancer Type, 2021-2034
  • Table 9: Global Veterinary Oncology Market Revenue (USD Billion) Forecast, By Animal Type, 2021-2034
  • Table 10: Global Veterinary Oncology Market Revenue (USD Billion) Forecast, By Region, 2021-2034
  • Table 11: North America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Offering, 2021-2034
  • Table 12: North America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Diagnostics, 2021-2034
  • Table 13: North America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 14: North America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Technique, 2021-2034
  • Table 15: North America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapeutics, 2021-2034
  • Table 16: North America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 17: North America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 18: North America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Cancer Type, 2021-2034
  • Table 19: North America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Animal Type, 2021-2034
  • Table 20: North America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 21: Europe Veterinary Oncology Market Revenue (USD Billion) Forecast, By Offering, 2021-2034
  • Table 22: Europe Veterinary Oncology Market Revenue (USD Billion) Forecast, By Diagnostics, 2021-2034
  • Table 23: Europe Veterinary Oncology Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 24: Europe Veterinary Oncology Market Revenue (USD Billion) Forecast, By Technique, 2021-2034
  • Table 25: Europe Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapeutics, 2021-2034
  • Table 26: Europe Veterinary Oncology Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 27: Europe Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 28: Europe Veterinary Oncology Market Revenue (USD Billion) Forecast, By Cancer Type, 2021-2034
  • Table 29: Europe Veterinary Oncology Market Revenue (USD Billion) Forecast, By Animal Type, 2021-2034
  • Table 30: Europe Veterinary Oncology Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Asia Pacific Veterinary Oncology Market Revenue (USD Billion) Forecast, By Offering, 2021-2034
  • Table 32: Asia Pacific Veterinary Oncology Market Revenue (USD Billion) Forecast, By Diagnostics, 2021-2034
  • Table 33: Asia Pacific Veterinary Oncology Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 34: Asia Pacific Veterinary Oncology Market Revenue (USD Billion) Forecast, By Technique, 2021-2034
  • Table 35: Asia Pacific Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapeutics, 2021-2034
  • Table 36: Asia Pacific Veterinary Oncology Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 37: Asia Pacific Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 38: Asia Pacific Veterinary Oncology Market Revenue (USD Billion) Forecast, By Cancer Type, 2021-2034
  • Table 39: Asia Pacific Veterinary Oncology Market Revenue (USD Billion) Forecast, By Animal Type, 2021-2034
  • Table 40: Asia Pacific Veterinary Oncology Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 41: Latin America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Offering, 2021-2034
  • Table 42: Latin America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Diagnostics, 2021-2034
  • Table 43: Latin America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 44: Latin America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Technique, 2021-2034
  • Table 45: Latin America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapeutics, 2021-2034
  • Table 46: Latin America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 47: Latin America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 48: Latin America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Cancer Type, 2021-2034
  • Table 49: Latin America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Animal Type, 2021-2034
  • Table 50: Latin America Veterinary Oncology Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 51: Middle East & Africa Veterinary Oncology Market Revenue (USD Billion) Forecast, By Offering, 2021-2034
  • Table 52: Middle East & Africa Veterinary Oncology Market Revenue (USD Billion) Forecast, By Diagnostics, 2021-2034
  • Table 53: Middle East & Africa Veterinary Oncology Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 54: Middle East & Africa Veterinary Oncology Market Revenue (USD Billion) Forecast, By Technique, 2021-2034
  • Table 55: Middle East & Africa Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapeutics, 2021-2034
  • Table 56: Middle East & Africa Veterinary Oncology Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 57: Middle East & Africa Veterinary Oncology Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 58: Middle East & Africa Veterinary Oncology Market Revenue (USD Billion) Forecast, By Cancer Type, 2021-2034
  • Table 59: Middle East & Africa Veterinary Oncology Market Revenue (USD Billion) Forecast, By Animal Type, 2021-2034
  • Table 60: Middle East & Africa Veterinary Oncology Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Veterinary Oncology Market Revenue Breakdown (USD Billion, %) By Region, 2025 & 2034
  • Figure 2: Global Veterinary Oncology Market Value Share (%), By Offering, 2025 & 2034
  • Figure 3: Global Veterinary Oncology Market Value Share (%), By Cancer Type, 2025 & 2034
  • Figure 4: Global Veterinary Oncology Market Value Share (%), By Animal Type, 2025 & 2034
  • Figure 5: Global Veterinary Oncology Market Value Share (%), By Region, 2025 & 2034
  • Figure 6: North America Veterinary Oncology Market Value (USD Billion), By Offering, 2025 & 2034
  • Figure 7: North America Veterinary Oncology Market Value Share (%), By Offering, 2025
  • Figure 8: North America Veterinary Oncology Market Value (USD Billion), By Cancer Type, 2025 & 2034
  • Figure 9: North America Veterinary Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 10: North America Veterinary Oncology Market Value (USD Billion), By Animal Type, 2025 & 2034
  • Figure 11: North America Veterinary Oncology Market Value Share (%), By Animal Type, 2025
  • Figure 12: North America Veterinary Oncology Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 13: North America Veterinary Oncology Market Value Share (%), By Country, 2025
  • Figure 14: Europe Veterinary Oncology Market Value (USD Billion), By Offering, 2025 & 2034
  • Figure 15: Europe Veterinary Oncology Market Value Share (%), By Offering, 2025
  • Figure 16: Europe Veterinary Oncology Market Value (USD Billion), By Cancer Type, 2025 & 2034
  • Figure 17: Europe Veterinary Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 18: Europe Veterinary Oncology Market Value (USD Billion), By Animal Type, 2025 & 2034
  • Figure 19: Europe Veterinary Oncology Market Value Share (%), By Animal Type, 2025
  • Figure 20: Europe Veterinary Oncology Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Veterinary Oncology Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Veterinary Oncology Market Value (USD Billion), By Offering, 2025 & 2034
  • Figure 23: Asia Pacific Veterinary Oncology Market Value Share (%), By Offering, 2025
  • Figure 24: Asia Pacific Veterinary Oncology Market Value (USD Billion), By Cancer Type, 2025 & 2034
  • Figure 25: Asia Pacific Veterinary Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 26: Asia Pacific Veterinary Oncology Market Value (USD Billion), By Animal Type, 2025 & 2034
  • Figure 27: Asia Pacific Veterinary Oncology Market Value Share (%), By Animal Type, 2025
  • Figure 28: Asia Pacific Veterinary Oncology Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Veterinary Oncology Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Veterinary Oncology Market Value (USD Billion), By Offering, 2025 & 2034
  • Figure 31: Latin America Veterinary Oncology Market Value Share (%), By Offering, 2025
  • Figure 32: Latin America Veterinary Oncology Market Value (USD Billion), By Cancer Type, 2025 & 2034
  • Figure 33: Latin America Veterinary Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 34: Latin America Veterinary Oncology Market Value (USD Billion), By Animal Type, 2025 & 2034
  • Figure 35: Latin America Veterinary Oncology Market Value Share (%), By Animal Type, 2025
  • Figure 36: Latin America Veterinary Oncology Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Veterinary Oncology Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Veterinary Oncology Market Value (USD Billion), By Offering, 2025 & 2034
  • Figure 39: Middle East & Africa Veterinary Oncology Market Value Share (%), By Offering, 2025
  • Figure 40: Middle East & Africa Veterinary Oncology Market Value (USD Billion), By Cancer Type, 2025 & 2034
  • Figure 41: Middle East & Africa Veterinary Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 42: Middle East & Africa Veterinary Oncology Market Value (USD Billion), By Animal Type, 2025 & 2034
  • Figure 43: Middle East & Africa Veterinary Oncology Market Value Share (%), By Animal Type, 2025
  • Figure 44: Middle East & Africa Veterinary Oncology Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Veterinary Oncology Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Veterinary Oncology Market Share (%), by Company, 2025